经胰蛋白酶处理的2型和3型脊髓灰质炎病毒在大鼠中的免疫原性。

Immunogenicity of trypsin treated type 2 and type 3 poliovirus in rats.

作者信息

Kersten G F, Lantinga M, Hazendonk T, Beuvery E C

机构信息

Department for Process and Product Development, National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.

出版信息

Biologicals. 1995 Jun;23(2):179-83. doi: 10.1006/biol.1995.0029.

DOI:10.1006/biol.1995.0029

PMID:7546661

Abstract

Oral polio vaccine will encounter the proteolytic enzyme trypsin during administration but inactivated polio vaccine not. To investigate the effect on the humoral immune response, rats were immunized intramuscularly with trypsin treated type 2 and type 3 poliovirus. IgG and IgM responses were determined as well as the neutralizing antibody titer. It is shown that the immunogenicity of type 2 poliovirus, unlike that of type 3, is hardly affected by trypsin treatment. For type 3, trypsin treatment results in an increase in IgM and neutralizing response. The IgG response decreases after trypsin treatment. The results indicate that IPV formulations may be improved by the addition of trypsin treated type 3, as suggested by Roivainen and Hovi (J Virol 1987; 61: 3749-3753) but not by the addition of trypsin treated type 2 poliovirus.

摘要

口服脊髓灰质炎疫苗在接种过程中会遇到蛋白水解酶胰蛋白酶，而灭活脊髓灰质炎疫苗则不会。为了研究对体液免疫反应的影响，用经胰蛋白酶处理的2型和3型脊髓灰质炎病毒对大鼠进行肌肉注射免疫。测定了IgG和IgM反应以及中和抗体滴度。结果表明，与3型脊髓灰质炎病毒不同，2型脊髓灰质炎病毒的免疫原性几乎不受胰蛋白酶处理的影响。对于3型，胰蛋白酶处理导致IgM和中和反应增加。胰蛋白酶处理后IgG反应降低。结果表明，如Roivainen和Hovi（《病毒学杂志》1987年；61：3749 - 3753）所建议的，通过添加经胰蛋白酶处理的3型脊髓灰质炎病毒可能会改进灭活脊髓灰质炎疫苗制剂，但添加经胰蛋白酶处理的2型脊髓灰质炎病毒则不行。